Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-05-23Clinical Trial Update: Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma [Phase 3]
Phase 3 trial comparing bortezomib-melphalan conditioning vs melphalan for frontline transplant-eligible multiple myeloma patients; study st…
-
CLINICAL_TRIALS trial_result · 2022-05-19Clinical Trial Update: Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating ixazomib citrate, pomalidomide, dexamethasone with stem cell transplant in relapsed or refractory multiple…
-
CLINICAL_TRIALS trial_result · 2022-05-11Clinical Trial Update: Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex [Phase 3]
Phase 3 trial in relapsed/refractory multiple myeloma comparing daratumumab/pomalidomide/dexamethasone versus pomalidomide/dexamethasone; re…
-
CLINICAL_TRIALS trial_result · 2022-05-11Clinical Trial Update: Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma [Phase 2]
Phase 2 trial investigating autologous stem cell transplant followed by maintenance therapy in elderly multiple myeloma patients; results po…
-
CLINICAL_TRIALS trial_result · 2022-05-09Clinical Trial Update: Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 trial evaluating panobinostat, carfilzomib, and dexamethasone in relapsed or refractory multiple myeloma; study terminated with post…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-05-09Clinical Trial Update: Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy [Phase 4]
Phase 4 trial update on ferric carboxymaltose for treating iron-deficiency anemia in cancer patients with multiple myeloma on chemotherapy; …
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance [Phase 2]
Phase 2 clinical trial evaluating lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while…
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: Panobinostat Biological Correlates Study [Phase 2]
Phase 2 clinical trial evaluating panobinostat with biological correlates in various lymphoma conditions has completed.
-
CLINICAL_TRIALS trial_result · 2022-05-03Clinical Trial Update: Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating selinexor with high-dose melphalan before autologous stem cell transplantation in multiple myeloma; study complet…
-
CLINICAL_TRIALS trial_result · 2022-04-20Clinical Trial Update: Effect of Vitamin C in Autologous Stem Cell Transplantations [Phase 2]
Phase 2 trial update evaluating the effect of Vitamin C in autologous stem cell transplantations for myeloma and lymphoma is completed.
-
CLINICAL_TRIALS trial_result · 2022-04-14Clinical Trial Update: Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide [Phase 2]
Phase 2 trial evaluating elotuzumab plus lenalidomide for serologic relapse/progression on lenalidomide in multiple myeloma; study terminate…
-
CLINICAL_TRIALS trial_result · 2022-03-29Clinical Trial Update: A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment [Phase 2]
Phase 2 trial of isatuximab with bortezomib, cyclophosphamide, and dexamethasone, followed by maintenance with isatuximab and lenalidomide i…
-
CLINICAL_TRIALS trial_result · 2022-03-28Clinical Trial Update: A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor [Phase 2]
Phase 2 trial evaluating isatuximab combined with pomalidomide and dexamethasone in multiple myeloma patients who had one prior line includi…
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 trial evaluating trametinib combined with the Akt inhibitor GSK2141795 in relapsed or refractory multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2022-02-17Clinical Trial Update: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma [Phase 1, Phase 2]
This clinical trial update reports on the safety and effectiveness of combining Nivolumab and Daratumumab in patients with multiple myeloma …
-
CLINICAL_TRIALS trial_result · 2022-02-15Clinical Trial Update: A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma [Phase 2]
Phase 2 trial assessing accelerated infusion rate of daratumumab in relapsed and refractory multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2022-02-11Clinical Trial Update: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma [Phase 3]
Phase 3 study evaluating pomalidomide with low-dose dexamethasone in relapsed/refractory multiple myeloma is being conducted; final results …
-
CLINICAL_TRIALS trial_result · 2022-02-02Clinical Trial Update: Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating the combination of panobinostat and carfilzomib in relapsed/refractory multiple myeloma has completed with posted…
-
CLINICAL_TRIALS trial_result · 2022-02-01Clinical Trial Update: GEM-CLARIDEX: Ld vs BiRd [Phase 3]
Phase 3 trial update comparing LD vs BiRD regimens in multiple myeloma; status is unknown.
-
CLINICAL_TRIALS trial_result · 2022-02-01Clinical Trial Update: A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 trial evaluating melphalan flufenamide (melflufen) plus dexamethasone in relapsed/refractory multiple myeloma has been completed wit…
-
CLINICAL_TRIALS trial_result · 2022-01-28Clinical Trial Update: A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM) [Phase 1, Phase 2]
Phase I/II study of Temferon in multiple myeloma with early relapse after frontline therapy; trial terminated with results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-01-27Clinical Trial Update: Optimising Renal Outcome in Myeloma Renal Failure [Phase 2]
Phase 2 trial update on optimizing renal outcome in myeloma-related kidney failure.
-
CLINICAL_TRIALS trial_result · 2022-01-27Clinical Trial Update: Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients [Phase 2]
Phase 2 trial evaluating carfilzomib with daratumumab, lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myel…
-
CLINICAL_TRIALS trial_result · 2022-01-21Clinical Trial Update: Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens [Phase 1, Phase 2]
Clinical trial evaluating vorinostat, lenalidomide, and dexamethasone in multiple myeloma refractory to prior lenalidomide-containing regime…
-
CLINICAL_TRIALS trial_result · 2022-01-21Clinical Trial Update: Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) [Phase 2]
Phase 2 trial evaluating allogeneic hematopoietic stem cell transplantation with ixazomib for high-risk multiple myeloma has completed; resu…